<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">inovmed</journal-id><journal-title-group><journal-title xml:lang="ru">Инновационная медицина Кубани</journal-title><trans-title-group xml:lang="en"><trans-title>Innovative Medicine of Kuban</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2541-9897</issn><publisher><publisher-name>Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.35401/2541-9897-2025-10-3-45-51</article-id><article-id custom-type="elpub" pub-id-type="custom">inovmed-1271</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Маркеры эпителиально-мезенхимального перехода как актуальные параметры стратификации риска ухудшения клинического прогноза пациентов с меланомой кожи ранних стадий</article-title><trans-title-group xml:lang="en"><trans-title>Epithelial Mesenchymal Transition Markers as Relevant Parameters for Risk Stratification of Poor Clinical Outcomes in Patients with Early-Stage Cutaneous Melanoma</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7337-4618</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пасечникова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Pasechnikova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пасечникова Елизавета Александровна, врач-онколог, ; ассистент кафедры онкологии с курсом торакальной хирургии</p><p>350063, Краснодар, ул. Митрофана Седина, 4</p></bio><bio xml:lang="en"><p>Elizaveta A. Pasechnikova, Oncologist, ; Assistant of the Department of Oncology with a Course of Thoracic Surgery</p><p>ulitsa Mitrofana Sedina 4, Krasnodar, 35</p></bio><email xlink:type="simple">pasechnikovali@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9610-5525</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кадомцев</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kadomtsev</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кадомцев Дмитрий Вадимович, врач-онколог</p><p>350063, Краснодар, ул. Митрофана Седина, 4</p></bio><bio xml:lang="en"><p>Dmitry V. Kadomtsev, Oncologist</p><p>ulitsa Mitrofana Sedina 4, Krasnodar, 35</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0572-1395</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Порханов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Porhanov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Порханов Владимир Алексеевич, д. м. н., профессор, академик РАН, главный врач; заведующий кафедрой онкологии с курсом торакальной хирурги</p><p>Краснодар</p></bio><bio xml:lang="en"><p>Vladimir A. Porhanov, Dr. Sci. (Med.), Professor, Academician of Russian Academy of Science, Chief Physician; Head of the Department of Oncology with a Course of Thoracic Surgery</p><p>Krasnodar</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2515-9125</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максименко</surname><given-names>С. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Maksimenko</surname><given-names>S. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Максименко Софья Дмитриевна, врач-патологоанатом</p><p>350063, Краснодар, ул. Митрофана Седина, 4</p></bio><bio xml:lang="en"><p>Sofia D. Maksimenko, Pathologis</p><p>ulitsa Mitrofana Sedina 4, Krasnodar, 350063</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Кубанский государственный медицинский университет; Клинический онкологический диспансер № 1</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kuban State Medical University; Clinical Oncology Dispensary No. 1</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Клинический онкологический диспансер № 1</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Clinical Oncology Dispensary No. 1</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Кубанский государственный медицинский университет; Научно-исследовательский институт – Краевая клиническая больница № 1 им. проф. С.В. Очаповского</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kuban State Medical University; Scientific Research Institute – Ochapovsky Regional Hospital No. 1</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>30</day><month>09</month><year>2025</year></pub-date><volume>10</volume><issue>3</issue><fpage>45</fpage><lpage>51</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Пасечникова Е.А., Кадомцев Д.В., Порханов В.А., Максименко С.Д., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Пасечникова Е.А., Кадомцев Д.В., Порханов В.А., Максименко С.Д.</copyright-holder><copyright-holder xml:lang="en">Pasechnikova E.A., Kadomtsev D.V., Porhanov V.A., Maksimenko S.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.innovmedkub.ru/jour/article/view/1271">https://www.innovmedkub.ru/jour/article/view/1271</self-uri><abstract><p>Цель исследования: Определение прогностической значимости маркеров эпителиально-мезенхимального перехода и их связь с клинико-морфологическими характеристиками меланомы кожи.Материалы и методы: Патологоанатомическое и иммуногистохимическое исследование гистологических образцов первичной опухоли было проведено у 101 пациента с меланомой кожи стадии pT1a–1b. В рамках исследования оценивалась экспрессия маркеров E-кадгерина, TWIST, виментина, Ki-67, Melan-A и S100.Результаты: Установлена значимая корреляция между экспрессией TWIST, виментина и E-кадгерина с глубиной инвазии, изъязвлением в первичной опухоли и риском прогрессирования. Прогрессирование заболевания наблюдалось у пациентов с TWIST &gt;20%, виментином &gt;20% и E-кадгерином &lt;80%. Изъязвление кожи достоверно ассоциировалось с более выраженным эпителиально-мезенхимальным профилем и более высокой вероятностью метастатического поражения.Заключение: Анализ полученных результатов подтверждает клиническое значение показателей эпителиально-мезенхимального перехода в качестве независимых предикторов исхода заболевания, одновременно подчёркивая ведущую роль феномена изъязвления как важного морфологического критерия риска прогрессирования патологии. Предложенная прогностическая модель, базирующаяся на оценке относительной экспрессии белков TWIST, виментина и E-кадгерина, обеспечивает достоверное распределение пациентов по категориям риска развития осложнений.</p></abstract><trans-abstract xml:lang="en"><p>Objective: To evaluate the prognostic significance of Epithelial Mesenchymal Transition (EMT) transition markers and their association with clinicopathological characteristics of cutaneous melanoma.Materials and Methods: Histopathological and immunohistochemical examination of primary tumor tissue samples was performed in 101 patients with cutaneous melanoma of stage pT1a–1b. The study evaluated the expression of E-cadherin, TWIST, vimentin, Ki-67, Melan-A, and S100 markers.Results: A significant correlation was identified between the expression of TWIST, vimentin, and E-cadherin and the depth of tumor invasion, primary tumor ulceration, and risk of progression. Disease progression was observed in patients with TWIST and vimentin expression levels &gt; 20%, and E-cadherin expression &lt; 80%. Ulceration of the skin was significantly associated with enhanced EMT features and a greater risk of metastatic dissemination.Conclusion: The analysis of the obtained results confirms the clinical significance of epithelial–mesenchymal transition markers as independent predictors of disease outcome, also emphasizes the key role of ulceration as an important morphological risk factor for disease progression. The proposed prognostic model, based on the assessment of relative expression levels of TWIST, vimentin, and E-cadherin, provides reliable classification of patients according to their risk of complication development.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>меланома</kwd><kwd>эпителиально-мезенхимальный переход</kwd><kwd>E-кадгерин</kwd><kwd>TWIST</kwd><kwd>прогностическая модель</kwd></kwd-group><kwd-group xml:lang="en"><kwd>melanoma</kwd><kwd>epithelial-mesenchymal transition</kwd><kwd>E-cadherin</kwd><kwd>TWIST</kwd><kwd>prognosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Георгиева А.Ю., Пасечникова Е.А., Кадомцев Д.В., Максименко С.Д., Порханов В.А., Бодня В.Н. и тд. Роль опухолевого микроокружения в механизмах канцерогенеза. Современные проблемы науки и образования. 2025;1:74. https://doi.org/10.17513/spno.33892</mixed-citation><mixed-citation xml:lang="en">Georgieva A, Pasechnikova E, Kadomtsev D, Maksimenko S, Porkhanov V, Bodnya V, et. al. The Role of the Tumor Microenvironment in the Mechanisms of Carcinogenesis. Modern Problems of Science and Education. 2025;1:74. https://doi.org/10.17513/spno.33892</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Пасечникова Е.А., Бодня В.Н., Шаров C.В., Кадомцев Д.В., Георгиева А.Ю., Стукань А.И. Жидкостная биопсия: современное состояние проблемы. Инновационная медицина Кубани. 2021;(3):57-63. https://doi.org/10.35401/2500-0268-2021-23-3-57-63</mixed-citation><mixed-citation xml:lang="en">Pasechnikova E.A., Bodnya V.N., Sharov S.V., Kadomtsev D.V., Georgieva A.Y., Stukan A.I. Liquid biopsy: the current state of the issue. Innovative Medicine of Kuban. 2021;(3):57-63. (In Russ.) https://doi.org/10.35401/2500-0268-2021-23-3-57-63</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Пасечникова Е.А., Бодня В.Н., Кадомцев Д.В., Георгиева А.Ю., Порханов В.А., Шевчук Д.Д. Патогенетические особенности эпителиально-мезенхимального перехода при онкологических заболеваниях. Инновационная медицина Кубани. 2022;(2):85-92. https://doi.org/10.35401/2541-9897-2022-25-2-85-92</mixed-citation><mixed-citation xml:lang="en">Pasechnikova E.A., Bodnya V.N., Kadomtsev D.V., Georgieva A.Yu., Porhanov V.A., Shevchuk D.D. The epithelial-tomesenchymal transition in cancer: pathogenetic features. Innovative Medicine of Kuban. 2022;(2):85-92. (In Russ.) https://doi.org/10.35401/2541-9897-2022-25-2-85-92</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Eggermont AM. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping. Recent Results Cancer Res. 2000;157:178-189. PMID: 10857171. https://doi.org/10.1007/978-3-642-57151-0_15</mixed-citation><mixed-citation xml:lang="en">Eggermont AM. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping. Recent Results Cancer Res. 2000;157:178-189. PMID: 10857171. https://doi.org/10.1007/978-3-642-57151-0_15</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hintsala HR, Haapasaari KM, Soini Y, Karihtala P. An immunohistochemical study of NFE2L2, KEAP1 and 8-hydroxy-2’-deoxyguanosine and the EMT markers SNAI2, ZEB1 and TWIST1 in metastatic melanoma. Histol Histopathol. 2017;32(2):129-136. PMID: 27170270. https://doi.org/10.14670/hh-11-778</mixed-citation><mixed-citation xml:lang="en">Hintsala HR, Haapasaari KM, Soini Y, Karihtala P. An immunohistochemical study of NFE2L2, KEAP1 and 8-hydroxy-2’-deoxyguanosine and the EMT markers SNAI2, ZEB1 and TWIST1 in metastatic melanoma. Histol Histopathol. 2017;32(2):129-136. PMID: 27170270. https://doi.org/10.14670/hh-11-778</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Damsky WE, Rosenbaum LE, Bosenberg M. Decoding melanoma metastasis. Cancers (Basel). 2010;3(1):126-163. PMID: 24212610. PMCID: PMC3756353. https://doi.org/10.3390/cancers3010126</mixed-citation><mixed-citation xml:lang="en">Damsky WE, Rosenbaum LE, Bosenberg M. Decoding melanoma metastasis. Cancers (Basel). 2010;3(1):126-163. PMID: 24212610. PMCID: PMC3756353. https://doi.org/10.3390/cancers3010126</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Roccuzzo G, Bongiovanni E, Tonella L, et al. Emerging prognostic biomarkers in advanced cutaneous melanoma: a literature update. Expert Rev Mol Diagn. 2024;24(1-2):49-66. PMID: 38334382. https://doi.org/10.1080/14737159.2024.2314574</mixed-citation><mixed-citation xml:lang="en">Roccuzzo G, Bongiovanni E, Tonella L, et al. Emerging prognostic biomarkers in advanced cutaneous melanoma: a literature update. Expert Rev Mol Diagn. 2024;24(1-2):49-66. PMID: 38334382. https://doi.org/10.1080/14737159.2024.2314574</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Weiss MB, Abel EV, Mayberry MM, Basile KJ, Berger AC, Aplin AE. TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Res. 2012;72(24):6382-6392. PMID: 23222305. PMCID: PMC3531871. https://doi.org/10.1158/0008-5472.can-12-1033</mixed-citation><mixed-citation xml:lang="en">Weiss MB, Abel EV, Mayberry MM, Basile KJ, Berger AC, Aplin AE. TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Res. 2012;72(24):6382-6392. PMID: 23222305. PMCID: PMC3531871. https://doi.org/10.1158/0008-5472.can-12-1033</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bertolesi GE, Debnath N, Heshami N, et al. Interplay of Light, Melatonin, and Circadian Genes in Skin Pigmentation Regulation. Pigment Cell Melanoma Res. 2025;38(1):e13220. PMID: 39825699. PMCID: PMC11742648. https://doi.org/10.1111/pcmr.13220</mixed-citation><mixed-citation xml:lang="en">Bertolesi GE, Debnath N, Heshami N, et al. Interplay of Light, Melatonin, and Circadian Genes in Skin Pigmentation Regulation. Pigment Cell Melanoma Res. 2025;38(1):e13220. PMID: 39825699. PMCID: PMC11742648. https://doi.org/10.1111/pcmr.13220</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Cazzato G, Sgarro N, Casatta N, Lupo C, Ingravallo G, Ribatti D. Epigenetics and Control of Tumor Angiogenesis in Melanoma: An Update with Therapeutic Implications. Cancers (Basel). 2024;16(16):2843. PMID: 39199614. PMCID: PMC11352434. https://doi.org/10.3390/cancers16162843</mixed-citation><mixed-citation xml:lang="en">Cazzato G, Sgarro N, Casatta N, Lupo C, Ingravallo G, Ribatti D. Epigenetics and Control of Tumor Angiogenesis in Melanoma: An Update with Therapeutic Implications. Cancers (Basel). 2024;16(16):2843. PMID: 39199614. PMCID: PMC11352434. https://doi.org/10.3390/cancers16162843</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wawrowicz K, Durak-Kozica M, Wierzbicki M, Stępień EŁ. Developing a Tumor Microenvironment in Rotating Human Melanoma Cell Cultures: Study of a Novel Preclinical Model. ACS Omega. 2025;10(25):27288-27300. PMID: 40621031. PMCID: PMC12223851. https://doi.org/10.1021/acsomega.5c02682</mixed-citation><mixed-citation xml:lang="en">Wawrowicz K, Durak-Kozica M, Wierzbicki M, Stępień EŁ. Developing a Tumor Microenvironment in Rotating Human Melanoma Cell Cultures: Study of a Novel Preclinical Model. ACS Omega. 2025;10(25):27288-27300. PMID: 40621031. PMCID: PMC12223851. https://doi.org/10.1021/acsomega.5c02682</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Pillai M, Rajaram G, Thakur P, et al. Mapping phenotypic heterogeneity in melanoma onto the epithelial-hybrid-mesenchymal axis. Front Oncol. 2022;12:913803. PMID: 36003764. PMCID: PMC9395132. https://doi.org/10.3389/fonc.2022.913803</mixed-citation><mixed-citation xml:lang="en">Pillai M, Rajaram G, Thakur P, et al. Mapping phenotypic heterogeneity in melanoma onto the epithelial-hybrid-mesenchymal axis. Front Oncol. 2022;12:913803. PMID: 36003764. PMCID: PMC9395132. https://doi.org/10.3389/fonc.2022.913803</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Falcone I, Conciatori F, Bazzichetto C, et al. Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. Cancers (Basel). 2020;12(10):2870. PMID: 33036192. PMCID: PMC7601592. https://doi.org/10.3390/cancers12102870</mixed-citation><mixed-citation xml:lang="en">Falcone I, Conciatori F, Bazzichetto C, et al. Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. Cancers (Basel). 2020;12(10):2870. PMID: 33036192. PMCID: PMC7601592. https://doi.org/10.3390/cancers12102870</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">De Oliveira Filho RS, de Oliveira DA, Nisimoto MM, Marti LC. A Review of Advanced Cutaneous Melanoma Therapies and Their Mechanisms, from Immunotherapies to Lysine Histone Methyl Transferase Inhibitors. Cancers (Basel). 2023;15(24):5751. PMID: 38136297. PMCID: PMC10741407. https://doi.org/10.3390/cancers15245751</mixed-citation><mixed-citation xml:lang="en">De Oliveira Filho RS, de Oliveira DA, Nisimoto MM, Marti LC. A Review of Advanced Cutaneous Melanoma Therapies and Their Mechanisms, from Immunotherapies to Lysine Histone Methyl Transferase Inhibitors. Cancers (Basel). 2023;15(24):5751. PMID: 38136297. PMCID: PMC10741407. https://doi.org/10.3390/cancers15245751</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Centeno PP, Pavet V, Marais R. The journey from melanocytes to melanoma. Nat Rev Cancer. 2023;23(6):372-390. PMID: 37095242. https://doi.org/10.1038/s41568-023-00565-7</mixed-citation><mixed-citation xml:lang="en">Centeno PP, Pavet V, Marais R. The journey from melanocytes to melanoma. Nat Rev Cancer. 2023;23(6):372-390. PMID: 37095242. https://doi.org/10.1038/s41568-023-00565-7</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y, Wang Z, Ajani JA, Song S. Drug resistance and Cancer stem cells. Cell Commun Signal. 2021;19(1):19. PMID: 33588867. PMCID: PMC7885480. https://doi.org/10.1186/s12964-020-00627-5</mixed-citation><mixed-citation xml:lang="en">Li Y, Wang Z, Ajani JA, Song S. Drug resistance and Cancer stem cells. Cell Commun Signal. 2021;19(1):19. PMID: 33588867. PMCID: PMC7885480. https://doi.org/10.1186/s12964-020-00627-5</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Pinzani P, D’Argenio V, Del Re M, et al. Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. Clin Chem Lab Med. 2021;59(7):1181-1200. PMID: 33544478. https://doi.org/10.1515/cclm-2020-1685</mixed-citation><mixed-citation xml:lang="en">Pinzani P, D’Argenio V, Del Re M, et al. Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. Clin Chem Lab Med. 2021;59(7):1181-1200. PMID: 33544478. https://doi.org/10.1515/cclm-2020-1685</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Pearlman RL, Montes de Oca MK, Pal HC, Afaq F. Potential therapeutic targets of epithelial-mesenchymal transition in melanoma. Cancer Lett. 2017;391:125-140. PMID: 28131904. PMCID: PMC5371401. https://doi.org/10.1016/j.canlet.2017.01.029</mixed-citation><mixed-citation xml:lang="en">Pearlman RL, Montes de Oca MK, Pal HC, Afaq F. Potential therapeutic targets of epithelial-mesenchymal transition in melanoma. Cancer Lett. 2017;391:125-140. PMID: 28131904. PMCID: PMC5371401. https://doi.org/10.1016/j.canlet.2017.01.029</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
